Heart and Vessels

, Volume 26, Issue 4, pp 370–378 | Cite as

Impact of chronic kidney disease on the severity of initially diagnosed coronary artery disease and the patient prognosis in the Japanese population

  • Hidenori Yagi
  • Makoto Kawai
  • Kimiaki Komukai
  • Takayuki Ogawa
  • Kosuke Minai
  • Tomohisa Nagoshi
  • Kazuo Ogawa
  • Hiroshi Sekiyama
  • Ikuo Taniguchi
  • Michihiro Yoshimura
Original Article


This study evaluated the relationship between the severity of coronary artery disease (CAD) and traditional coronary risk factors, metabolic syndrome, and chronic kidney disease (CKD). Three hundred and forty-three patients (35–90 years of age) with initial diagnosis of CAD were separated into two groups: 165 patients with single-vessel coronary artery disease (SVD group) and 178 patients with multivessel coronary artery disease (MVD group). We compared the risk factors for CAD between the two groups. An adjusted multivariate analysis showed that only CKD was associated with MVD (odds ratio, 2.85; 95% confidence interval [CI], 1.76–4.63; P = 0.00002). Next, the relationship between the severity of CAD, CKD, and the incidence of subsequent major adverse cardiac event (MACE) was investigated in 338 patients during the patient follow-up. The risk of MACE was approximately threefold higher in the group with MVD and CKD stage of 3 or greater than in the group with SVD but without CKD stage of 3 or greater (adjusted hazard ratio, 3.40; 95% CI, 1.26–9.17; P = 0.016). A statistical analysis also suggested that having MVD and advanced CKD was a more powerful risk factor for MACE. The comparison of risk factors between patients with SVD and patients with MVD revealed that CKD was the most important risk factor for MVD. In addition, having MVD and advanced CKD together was a crucial risk factor for subsequent MACE. To reduce the progression of CAD and to improve the prognosis of patients with MVD, the renal status should therefore be carefully assessed during treatment for CAD.


Chronic kidney disease Coronary artery disease Multivessel disease 


  1. 1.
    Mark DB, Nelson CL, Califf RM, Harrell FE Jr, Lee KL, Jones RH, Fortin DF, Stack RS, Glower DD, Smith LR (1994) Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 89:2015–2025PubMedGoogle Scholar
  2. 2.
    Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, Kaiser GC, Alderman E, Killip T 3rd (1994) Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 90:2645–2657PubMedGoogle Scholar
  3. 3.
    Anderson KM, Wilson PW, Odell PM KWB (1991) An updated coronary risk profile. A statement for health professionals. Circulation 83:356–362PubMedGoogle Scholar
  4. 4.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMedGoogle Scholar
  5. 5.
    Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRefGoogle Scholar
  6. 6.
    Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778PubMedCrossRefGoogle Scholar
  7. 7.
    Meisinger C, Döring A, Löwel H, for the KORA Study Group (2006) Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 27:1245–1250PubMedCrossRefGoogle Scholar
  8. 8.
    Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:403–414PubMedCrossRefGoogle Scholar
  9. 9.
    Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169PubMedCrossRefGoogle Scholar
  10. 10.
    Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285–1295PubMedCrossRefGoogle Scholar
  11. 11.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRefGoogle Scholar
  12. 12.
    Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100PubMedCrossRefGoogle Scholar
  13. 13.
    Sawara Y, Takei T, Uchida K, Tsuchiya K, Nitta K (2009) Metabolic syndrome and anthropometric factors in Japanese patients with chronic kidney disease. Heart Vessels 24:199–203PubMedCrossRefGoogle Scholar
  14. 14.
    Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T (2006) The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264–1271PubMedCrossRefGoogle Scholar
  15. 15.
    Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M (2005) Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 68:228–236PubMedCrossRefGoogle Scholar
  16. 16.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444PubMedCrossRefGoogle Scholar
  17. 17.
    Takaoka K, Yoshimura M, Ogawa H, Kugiyama K, Nakayama M, Shimasaki Y, Mizuno Y, Sakamoto T, Yasue H (2000) Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. Int J Cardiol 72:121–126PubMedCrossRefGoogle Scholar
  18. 18.
    Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K (1998) A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103:65–69PubMedCrossRefGoogle Scholar
  19. 19.
    Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K (1999) T-786 → C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99:2864–2870PubMedGoogle Scholar
  20. 20.
    Nakayama M, Yoshimura M, Sakamoto T, Shimasaki Y, Nakamura S, Ito T, Abe K, Yamamuro M, Miyamoto Y, Saito Y, Nakao K, Yasue H, Ogawa H (2003) Synergistic interaction of T-786 → C polymorphism in the endothelial nitric oxide synthase gene and smoking for an enhanced risk for coronary spasm. Pharmacogenetics 13:683–688PubMedCrossRefGoogle Scholar
  21. 21.
    Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB (1975) A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51(Suppl):5–40PubMedGoogle Scholar
  22. 22.
    Okamura T, Tanaka H, Miyamatsu N, Hayakawa T, Kadowaki T, Kita Y, Nakamura Y, Okayama A, Ueshima H, NIPPON DATA80 Research Group (2007) The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 190:216–223PubMedCrossRefGoogle Scholar
  23. 23.
    Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMedGoogle Scholar
  24. 24.
    Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity (2002) New criteria for ‘obesity disease’ in Japan. Circ J 66:987–992CrossRefGoogle Scholar
  25. 25.
    Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA (2006) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113:e463–e654PubMedCrossRefGoogle Scholar
  26. 26.
    The International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
  27. 27.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRefGoogle Scholar
  28. 28.
    Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB, Intermountain Heart Collaborative Study Group (2003) Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 42:57–63PubMedCrossRefGoogle Scholar
  29. 29.
    Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116:85–97PubMedCrossRefGoogle Scholar
  30. 30.
    Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW (2009) Sympathetic activation in chronic renal failure. J Am Soc Nephrol 20:933–939PubMedCrossRefGoogle Scholar
  31. 31.
    Ambrose JA, Barua RS (2004) The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43:1731–1737PubMedCrossRefGoogle Scholar
  32. 32.
    Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH (1987) Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 317:1303–1309PubMedCrossRefGoogle Scholar
  33. 33.
    Holbrook JH, Grundy SM, Hennekens CH, Kannel WB, Strong JP (1984) Cigarette smoking and cardiovascular diseases. A statement for health professionals by a task force appointed by the steering committee of the American Heart Association. Circulation 70:1114A–1117APubMedGoogle Scholar
  34. 34.
    Gotto AM Jr (1986) Interactions of the major risk factors for coronary heart disease. Am J Med 80:48–55PubMedCrossRefGoogle Scholar
  35. 35.
    Yagi H, Komukai K, Hashimoto K, Kawai M, Ogawa T, Anzawa R, Minai K, Nagoshi T, Ogawa K, Taniguchi I, Yoshimura M (2010) Difference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndrome. J Cardiol 55:345–353Google Scholar
  36. 36.
    Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ (2004) Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291:451–459PubMedCrossRefGoogle Scholar
  37. 37.
    Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB (2005) Survival advantages of obesity in dialysis patients. Am J Clin Nutr 81:543–554PubMedGoogle Scholar
  38. 38.
    Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, Lima JJD, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F, for the AURORA Study Group (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Hidenori Yagi
    • 1
  • Makoto Kawai
    • 1
  • Kimiaki Komukai
    • 1
  • Takayuki Ogawa
    • 1
  • Kosuke Minai
    • 1
  • Tomohisa Nagoshi
    • 1
  • Kazuo Ogawa
    • 1
  • Hiroshi Sekiyama
    • 1
  • Ikuo Taniguchi
    • 1
  • Michihiro Yoshimura
    • 1
  1. 1.Division of Cardiology, Department of Internal MedicineThe Jikei University School of MedicineTokyoJapan

Personalised recommendations